[HTML][HTML] Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
Journal of Clinical Oncology, 2008•ncbi.nlm.nih.gov
Purpose Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective
against HER-2–positive locally advanced or metastatic breast cancer (MBC). This phase III
trial evaluated the efficacy of lapatinib in HER-2–negative and HER-2–uncharacterized
MBC.
(EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective
against HER-2–positive locally advanced or metastatic breast cancer (MBC). This phase III
trial evaluated the efficacy of lapatinib in HER-2–negative and HER-2–uncharacterized
MBC.
Abstract
Purpose
Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2–positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy of lapatinib in HER-2–negative and HER-2–uncharacterized MBC.
ncbi.nlm.nih.gov
